Treatment of antipsychotic-related Akathisia revisited: The role of serotonin 2a receptor antagonists

Journal of Clinical Psychopharmacology

Volumn 35, Issue 6, 2015, Pages 711-714

  Poyurovsky, Michael ^a   Weizman, Abraham ^b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

antipsychotic related akathisia; low dose mirtazapine; serotonin 2A receptor antagonism

Indexed keywords

PROPRANOLOL; SEROTONIN 2A ANTAGONIST; NEUROLEPTIC AGENT; SEROTONIN 2 ANTAGONIST;

AKATHISIA; ANTIPSYCHOTIC RELATED AKATHISIA; ARTICLE; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; META ANALYSIS (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); AKATHISIA, DRUG-INDUCED;

AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; HUMANS; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS;

EID: 84947019994     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000412     Document Type: Article

References (22)

1. Tenback DE, van Harten PN, Slooff CJ, et al. Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10, 000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Am J Psychiatry. 2006;163:1438-1440.
2. Kane JM, Fleischhacker WW, Hansen L, et al. Akathisia: an updated review focusing on second-generation antipsychotics. J Clin Psychiatry. 2009;70:627-643.
3. Hansen L. A critical review of akathisia, and its possible association with suicidal behaviour. Hum Psychopharmacol. 2001;16:495-505.
4. Poyurovsky M, Weizman A. Serotonin-based pharmacotherapy for acute neuroleptic-induced akathisia: a new approach to an old problem. Br J Psychiatry. 2001;179:4-8.
5. Kumar R, Sachdev PS. Akathisia and second-generation antipsychotic drugs. Curr Opin Psychiatry. 2009;22:293-299.
6. Rummel-Kluge C, Komossa K, Schwarz S, et al. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull. 2012;38: 167-177.
7. Gao K, Kemp DE, Ganocy SJ, et al. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol. 2008;28:203-209.
8. Tarazi FI, Stahl SM. Iloperidone, asenapine and lurasidone: a primer on their current status. Expert Opin Pharmacother. 2012;13:1911-1922.
9. Veselinovi T, Paulzen M, Gründer G. Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression. Expert Rev Neurother. 2013;13:1141-1159.
10. Pringsheim T, Doja A, Belanger S, et al. Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youth. Paediatr Child Health. 2011;16: 590-598.
11. Lima AR, Bacalcthuk J, Barnes TR, et al. Central action beta-blockers versus placebo for neuroleptic-induced acute akathisia [Review]. Cochrane Database Syst Rev. 2004;18:CD001946.
12. Rathbone J, Soares-Weiser K. Anticholinergics for neuroleptic-induced acute akathisia [Review]. Cochrane Database Syst Rev. 2006; 18:CD003727.
13. Lima AR, Soares-Weiser K, Bacaltchuk J, Benzodiazepines for neuroleptic-induced acute akathisia [Review]. Cochrane Database Syst Rev. 2002;CD001950.
14. Poyurovsky M. Acute antipsychotic-induced akathisia revisited. Br J Psychiatry. 2010;196:89-91.
15. Grainger MM, Ahlbrand R, Horn PS, et al. Receptor binding targets for antipsychotic efficacy. In: Ritsner MS, ed. Polypharmacy in Psychiatry Practice, Volume I: Multiple Medications Use Strategies. Dordrecht: Springer Publishers; 2013:25-43.
16. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther. 1989;251:238-246.
17. Laoutidis ZG, Luckhaus C. 5-HT2A receptor antagonists for the treatment of neuroleptic-induced akathisia: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2014;17:823-832.
18. Poyurovsky M, Pashinian A, Weizman R, et al. Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia. A randomized, double-blind, placebo-and propranolol-controlled trial. Biol Psychiatry. 2006;59:1071-1077.
19. Poyurovsky M, Bergman J, Pashinian A, et al. Beneficial effect of low-dose mirtazapine in acute aripiprazole-induced akathisia. Int Clin Psychopharmacol. 2014;29:296-298.
20. Poyurovsky M, Weizman R, Weizman A. Aripiprazole's receptor pharmacology and extrapyramidal side effects. Am J Psychiatry. 2008;165:398.
21. Fischel T, Hermesh H, Aizenberg D, et al. Cyproheptadine versus propranolol for the treatment of acute neuroleptic-induced akathisia: a comparative double-blind study. J Clin Psychopharmacol. 2001;21: 612-615.
22. Stryjer R, Rosenzcwaig S, Bar F, et al. Trazodone for the treatment of neuroleptic-induced acute akathisia: a placebo-controlled, double-blind, crossover study. Clin Neuropharmacol. 2010;33:219-222.